Cure My Disease

Don't miss your cure!

 Log in / Sign up

Stroke care at a distance: can video consultations speed up Life-Saving treatment?

NCT ID NCT07721129

Disease control Sponsor: Oman Ministry of Health Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 22, 2026 · Last updated Jul 23, 2026 · Updated 1 time

Summary

This trial tests whether a TeleStroke network can help peripheral hospitals in Oman safely give clot-busting drugs (alteplase or tenecteplase) to people having an acute ischemic stroke. A remote neurologist will assess patients via video, review scans, and guide the local medical team. The goal is to see if this approach increases the number of patients treated within the critical 4.5-hour window and improves their recovery.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
clot-busting drugs (alteplase or tenecteplase) given through a vein, guided by a remote neurologist via video
What this could lead to
If it works, this could expand access to emergency stroke treatment in underserved areas, potentially reducing disability and death from stroke.
What could go wrong
This is a relatively small, region-specific trial. The benefit depends on reliable technology and quick coordination, which may not work in all settings. There is a risk of bleeding from the clot-busting drugs.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

About 200 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Aug 2026

An estimate. Start dates often move.

Expected to finish

Mar 2027

An estimate. End dates often move.

Lead sponsor

A government agency

The lead sponsor is a government body.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age \>18 years. Acute neurologic deficits due to cerebral ischemia/infarction. Clearly defined onset with duration from stroke onset of \<4.5 hours. Significant neurological deficit (usually NIHSS score of 4-25). Exclusion Criteria: * CT brain shows showing evidence of intracranial hemorrhage * CT brain showing acute or subacute infarct of size about \>1/3 Middle Cerebral Artery territory. * Arterial puncture at non compressible site in previous 7 days * History of previous intracranial hemorrhage. * Intracranial neoplasm, AV malformation, or aneurysm * Recent head injury OR intracranial or intraspinal surgery in last 3 mo. * Persistent Elevated BP \>185/110 mm Hg despite treatment. * Active ongoing internal bleeding. * Platelet count \<100 000/mm3. * Current use of NOACs OR warfarin with INR \>1.7 OR Inj.Enoxaparin/Heparin in therapeutic dose * Blood glucose concentration \<2.7mmol/L (\<50mg/dl). Relative contraindications: (may consider IV alteplase on individual evaluation). * Seizure at onset with post ictal residual neurological deficit. * Signs of mild stroke in isolation or rapidly improving symptoms. * Pregnancy. * Recent GI or UT hemorrhage within the last 21 days. * Recent MI within previous 3 months (to exclude anterolateral infarct / STEMI)

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Ischemic stroke are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

ischemic stroke stroke disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Ischemic stroke Ischemic stroke, acute

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  2. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

More trials for these conditions

Other studies related to the condition(s) this trial covers.